<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 31 Mar 2021 07:22:18 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>索马鲁肽启动NASH三期临床</title><link>https://mp.weixin.qq.com/s/96v3mbqkGiQmpSRpkhVyFA</link><description></description><content:encoded><![CDATA[索马鲁肽启动NASH三期临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>天境生物Claudin 18.2/4-1BB双抗获FDA批准临床</title><link>https://mp.weixin.qq.com/s/jC5WZmTEJcoS6lNcfAdt-g</link><description></description><content:encoded><![CDATA[天境生物Claudin 18.2/4-1BB双抗获FDA批准临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>齐鲁制药免疫毒素Vicineum启动三期临床</title><link>https://mp.weixin.qq.com/s/vc6QdTJUpGJnxiTh8InZCw</link><description></description><content:encoded><![CDATA[齐鲁制药免疫毒素Vicineum启动三期临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>信达生物申报PD-1/TIGIT双抗，国内首个</title><link>https://mp.weixin.qq.com/s/SLYWnMjy0Ao69NhTY_trgA</link><description></description><content:encoded><![CDATA[信达生物申报PD-1/TIGIT双抗，国内首个]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>信达生物2020营收38亿元，研发费用18亿元</title><link>https://mp.weixin.qq.com/s/9IvkuQWIOjlAok2iz8NCfQ</link><description></description><content:encoded><![CDATA[信达生物2020营收38亿元，研发费用18亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>天境生物2020营收15亿元，净利润4.7亿元</title><link>https://mp.weixin.qq.com/s/36HVU7CBdzhHZ3P8anHmfw</link><description></description><content:encoded><![CDATA[天境生物2020营收15亿元，净利润4.7亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>复星/复宏汉霖生物类似药2020销售额8.86亿元</title><link>https://mp.weixin.qq.com/s/PMWdZGk6ICIjvMw0GTWLtw</link><description></description><content:encoded><![CDATA[复星/复宏汉霖生物类似药2020销售额8.86亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药</title><link>https://mp.weixin.qq.com/s/o6cnSzPY_eyuWGFPV9qKmQ</link><description></description><content:encoded><![CDATA[PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药]]></content:encoded><pubDate>Mon, 29 Mar 2021 10:32:11 +0800</pubDate></item><item><title>M7824之后TGFβ前路何在：整合素αvβ8更具潜力</title><link>https://mp.weixin.qq.com/s/kjZdxXcORgZejgUbQZKkfA</link><description></description><content:encoded><![CDATA[M7824之后TGFβ前路何在：整合素αvβ8更具潜力]]></content:encoded><pubDate>Sun, 28 Mar 2021 08:10:36 +0800</pubDate></item><item><title>永泰生物技术全梳理</title><link>https://mp.weixin.qq.com/s/6qW4s3gg2Dl_ecYkTLurZA</link><description></description><content:encoded><![CDATA[永泰生物技术全梳理]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元</title><link>https://mp.weixin.qq.com/s/EKiqpjD1jOxKmnjHcgwNJA</link><description></description><content:encoded><![CDATA[Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>1比19：FDA专家委员会拒绝批准NGF抗体Tanezumab</title><link>https://mp.weixin.qq.com/s/qmSlnqYGHQWkK_X6-gr3kQ</link><description></description><content:encoded><![CDATA[1比19：FDA专家委员会拒绝批准NGF抗体Tanezumab]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Nature：反义寡核苷酸药物（ASO）综述与展望</title><link>https://mp.weixin.qq.com/s/Hg2n4utLCS2ly7WbK-ukOQ</link><description></description><content:encoded><![CDATA[Nature：反义寡核苷酸药物（ASO）综述与展望]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Science：发现袋鼠第3种T细胞，γμT细胞</title><link>https://mp.weixin.qq.com/s/12M3l_qsU7Grlt2AX6iZlg</link><description></description><content:encoded><![CDATA[Science：发现袋鼠第3种T细胞，γμT细胞]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>华夏英泰：STAR-T对于实体瘤极具潜力</title><link>https://mp.weixin.qq.com/s/_x0Uz8PXpyEV9awshETtCQ</link><description></description><content:encoded><![CDATA[华夏英泰：STAR-T对于实体瘤极具潜力]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>三特异性CAR-T：CD19/CD20/CD22</title><link>https://mp.weixin.qq.com/s/pkqH_fLbKBpBpKEqAEqe5g</link><description></description><content:encoded><![CDATA[三特异性CAR-T：CD19/CD20/CD22]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局</title><link>https://mp.weixin.qq.com/s/rNnYXXuPHrgNVBqba6Xknw</link><description></description><content:encoded><![CDATA[百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局]]></content:encoded><pubDate>Tue, 23 Mar 2021 23:27:14 +0800</pubDate></item><item><title>盘点三地上市的中国生物医药企业</title><link>https://mp.weixin.qq.com/s/hxwB9S7PMRMMHncD5LRfVA</link><description></description><content:encoded><![CDATA[盘点三地上市的中国生物医药企业]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>抑制性白细胞免疫球蛋白样受体：LILRB</title><link>https://mp.weixin.qq.com/s/6l-81xplg9DPpIPLNx0EeA</link><description></description><content:encoded><![CDATA[抑制性白细胞免疫球蛋白样受体：LILRB]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>大分子CDMO乘风破浪：原核、抗体、基因治疗</title><link>https://mp.weixin.qq.com/s/QDdzmuawFXYE6ZmTHm5YAQ</link><description></description><content:encoded><![CDATA[大分子CDMO乘风破浪：原核、抗体、基因治疗]]></content:encoded><pubDate>Mon, 22 Mar 2021 13:19:48 +0800</pubDate></item></channel></rss>